Healthcare / BiotechnologyHKSE
$2.50
+0.20 (+8.70%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-200.8M · quality 65.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
16/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.2B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-109.6%
↓Gross Margin
24.6%
↓Debt/Equity
0.47
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-521.6%
FCF / Net income
0.85x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $32.7M · net income $-200.1M · FCF $-170.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $32.7M | $32.7M | $5.0M | — | — |
| Net Income | $-200.1M | $-200.1M | $-155.3M | $-1.06B | $-954.4M |
| EBITDA | $-165.8M | $-165.8M | $-128.4M | $-1.04B | $-926.7M |
| EPS | — | — | -0.36 | -2.47 | -2.53 |
| Gross Margin | 24.6% | 24.6% | -94.6% | — | — |
| Operating Margin | -530.3% | -530.3% | -3062.7% | — | — |
| Net Margin | -612.3% | -612.3% | -3105.8% | — | — |
| Balance Sheet | |||||
| Debt/Equity | 0.47 | 0.47 | 0.45 | 0.55 | 0.19 |
| Current Ratio | 0.43 | 0.43 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-170.5M | $-170.5M | $-200.8M | $-390.3M | $-988.9M |
| Returns | |||||
| ROE | -109.6% | -109.6% | -52.8% | -231.6% | -63.8% |
| Valuation | |||||
| P/B | 6.42 | 6.42 | 1.38 | 1.44 | 2.68 |
| Growth & Yield | |||||
| Revenue Growth | 553.6% | 553.6% | — | — | — |
| EPS Growth | — | — | 85.4% | 2.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+78.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.36 → n/d
Residual
+78.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.